NASDAQ$DNTH
Dianthus Therapeutics Inc · Q2 2025 earnings
Q2 2025 earnings ·
Briefing
Dianthus Therapeutics reported Q2 2025, revenue of $193K, a net loss of $31.6M.
For Q2 2025, Dianthus Therapeutics reported Revenue was $193K; net loss was $31.6M. Management discusses operating trends, liquidity, capital priorities, and sector risks in the quarterly filing.
- Revenue $193K.
- Net loss $31.6M.
- Dianthus Therapeutics MD&A highlights liquidity, capital, and core operating trends.
- Macro and competitive factors shape year-over-year comparisons.
Headline financials
Revenue & EPS history
Dianthus Therapeutics Inc · Revenue · Quarterly
$193K
Forward guidance
Dianthus Therapeutics focuses on clinical milestones, funding runway, and pipeline progress in MD&A.
Tailwinds
- Pipeline advancement and trial readouts.
- Cash runway supports ongoing R&D.
- Partnership or licensing optionality.
Headwinds
- Trial timing and regulatory uncertainty.
- Funding needs and potential dilution.
- Pre-revenue or early commercial stage limits near-term profitability.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 15 quarterly earnings reports · overlaid with Q2 2025
+1.6%
Avg return
Earnings day
-2.3%
Avg return
5 days after
+1.9%
Avg return
30 days after
73%
11 / 15 earnings
Positive
+11.1%
Q2 2019
Best reaction
-6.1%
Q2 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.1% | -2.9% | -5.8% | |
| Q4 2025 | +9.7% | -1.7% | +15.7% | |
| Q3 2025 | +1.6% | +10.3% | +33.3% | |
| Q2 2025 | -6.1% | -2.4% | +30.0% | |
| Q1 2025 | +2.5% | +0.5% | -7.5% | |
| Q3 2023 | +0.4% | -0.5% | -16.4% | |
| Q2 2023 | +2.5% | -1.2% | -8.6% | |
| Q3 2020 | -0.9% | -1.4% | +11.7% | |
| Q2 2020 | +0.6% | +0.0% | -8.3% | |
| Q1 2020 | +2.7% | -1.3% | +5.4% | |
| Q3 2019 | -2.2% | -13.5% | +21.2% | |
| Q2 2019 | +11.1% | -0.8% | -13.2% | |
| Q1 2019 | +2.7% | +9.9% | -10.7% | |
| Q3 2018 | -3.4% | -24.7% | -14.1% | |
| Q2 2018 | +1.2% | -4.2% | -4.7% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro